This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Martini JF , Plimack ER , Choueiri TK , McDermott DF , Puzanov I , Fishman MN , Cho DC , Vaishampayan U , Rosbrook B , Fernandez KC , Tarazi JC , George S , Atkins MB
Angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment in patients with advanced renal cell carcinoma
Clin Cancer Res. 2020 Nov;26(21) :5598-5608
PMID: 32816890 URL: https://www.ncbi.nlm.nih.gov/pubmed/32816890
AbstractPURPOSE: Combined axitinib/pembrolizumab is approved for advanced renal cell carcinoma (aRCC). This exploratory analysis examined associations between angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment. EXPERIMENTAL DESIGN: Prospectively defined retrospective correlative exploratory analyses tested biospecimens from 52 treatment-naïve patients receiving axitinib and pembrolizumab (starting doses 5 mg twice-daily and 2 mg/kg every 3 weeks). Tumor tissue, serum, and whole blood samples were collected at baseline, and at cycle 2, day 1 (C2D1), and end of treatment (EOT) for blood-based samples. Clinical outcomes were objective response rate (ORR) and progression-free survival (PFS). RESULTS: Higher baseline tumor levels of CD8 showed a trend toward longer PFS (hazard ratio [HR] 0.4; P = 0.091). Higher baseline serum levels of CXCL10 (P = 0.0197) and CEACAM1 (P = 0.085) showed a trend toward better ORR and longer PFS, respectively. Patients for whom IL-6 was not detected at baseline had longer PFS vs patients for whom it was detected (HR 0.4; P = 0.028). At C2D1 and/or EOT, mainly immune-related biomarkers showed any association with better outcomes. The genes CA9 (P = 0.084), HIF1A (P = 0.064), and IFNG (P = 0.073) showed trending associations with ORR, and AKT3 (P = 0.0145), DDX58 (P = 0.0726), GZMA (P = 0.0666), LCN2 (NGAL; P = 0.0267), and PTPN11 (P = 0.0287) with PFS. CONCLUSIONS: With combined axitinib/pembrolizumab treatment in patients with aRCC, mostly immune-related biomarkers are associated with better treatment outcomes. This exploratory analysis has identified some candidate biomarkers to consider in future prospective testing. ClinicalTrials.gov identifier: NCT02133742.
NotesMartini, Jean-Francois Orcid: 0000-0001-8570-1401 Plimack, Elizabeth R Choueiri, Toni K McDermott, David F Puzanov, Igor Fishman, Mayer N Cho, Daniel C Vaishampayan, Ulka Rosbrook, Brad Fernandez, Kathrine C Tarazi, Jamal C Orcid: 0000-0002-5452-2061 George, Saby Orcid: 0000-0002-0444-5870 Atkins, Michael B Journal Article United States Clin Cancer Res. 2020 Aug 18:clincanres.1408.2020. doi: 10.1158/1078-0432.CCR-20-1408.